Deciphera Pharmaceuticals, Inc.

Release Summary

Pharmacokinetic (PK), Safety, and Tolerability Profile of DDCC-2618 in a Phase 1 Clinical Trial Supports 150mg QD Selected for a Pivotal Phase 3 Study

Deciphera Pharmaceuticals, Inc.